Thrombolysis: Newer thrombolytic agents and their role in clinical medicine

Heart

Volumn 89, Issue 11, 2003, Pages 1358-1362

  Nordt, Thomas K ^a,b   Bode, Christoph ^c  

^a KATHARINENHOSPITAL   (Germany)

^b Katherinenhospital   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LANOTEPLASE; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; ESCHERICHIA COLI; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

EID: 0142209155     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.11.1358     Document Type: Review

References (14)

1. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-8.
2. GUSTO III Investigators. A comparison of reteplase for acute myocardial infarction, N Engl J Med 1997;337:1118-23. The landmark clinical study that established reteplase as a thrombolytic agent equally as effective as accelerated alteplase, the gold standard, with respect to mortality after 30 days, the most decisive end point in clinical studies optimising the treatment of acute myocardial infarction.
3. van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999;137:786-91.
4. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.
5. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-22. The landmark clinical study that established tenecteplase as a thrombolytic agent in the treatment of acute myocardial infarction, proving as equally effective as accelerated alteplase with respect to mortality after 30 days.
6. Nordt TK, Moser M, Kohler B, et al. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost 1999;82(suppl):121-3.
7. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998;98:2117-25.
8. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005-13.
9. Nordt TK, Moser M, Kohler B, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haemost 1998;80:881-6. A clinical study in patients with acute myocardial infarction treated with thrombolytic therapy, supporting the dominant role of platelets in reocclusion in comparison with plasmatic coagulation and the endogenous fibrinolytic system.
10. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the TIMI 14 trial. Circulation 1999;99:2710-32.
11. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000;101:239-43. A clinical study that has brought the importance of myocardial microvascular reperfusion therapy in the treatment of myocardial infarction to new attention.
12. SPEED Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788-94.
13. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
14. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.